1887
Editorials Open Access
Like 0

Abstract

The development of efficient human papillomavirus (HPV) vaccines has required long lasting and tremendous research and development efforts by both academia and industry. However, their availability now turns out to be a major challenge for the public health services of many member states within the European Union (EU) and beyond.

Loading

Article metrics loading...

/content/10.2807/ese.13.33.18951-en
2008-08-14
2017-11-21
http://instance.metastore.ingenta.com/content/10.2807/ese.13.33.18951-en
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/13/33/art18951-en.htm?itemId=/content/10.2807/ese.13.33.18951-en&mimeType=html&fmt=ahah
Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error